Exporting Medical Cannabis from Thailand to Australia: A Practical Compliance Guide

Australia is one of the most commercially significant and most technically demanding export markets for Thai medical cannabis. The TGA applies a rigorous import framework that requires exporters to navigate both Thai export requirements and Australian import conditions simultaneously, with each permit application sequenced correctly before any shipment can move.

TGA Import Framework

Medical cannabis imported into Australia must be either a registered therapeutic good or supplied under the TGA's Special Access Scheme (SAS) or Authorised Prescriber (AP) pathway. The vast majority of imported medical cannabis enters under SAS Category B, which allows prescribers access to unapproved therapeutic goods for individual patients with demonstrated clinical need. Thai exporters are not selling directly to Australian patients or pharmacies: they are selling to licensed importers who manage the downstream regulatory relationship. The Australian importer holds the applicable licenses, applies for the import permits, and is responsible for the product once it clears Australian customs.

ODC Import Permit Requirements

Every shipment requires an Office of Drug Control (ODC) import permit specifying the product, quantity, supplier details, and destination facility. The Australian importer applies for this permit, and its issuance is a prerequisite for the Thai exporter's ONCB export authorization application. The two authorizations must be aligned before any shipment can proceed: the Thai ONCB will not issue export authorization without confirmation that the destination country import permit exists. This sequencing is the most consistent source of timeline delays for operators who begin the Thai export authorization process before the Australian ODC permit is confirmed.

Product Quality Requirements

TGA import conditions specify minimum quality standards that Thai exporters must meet before a shipment will be accepted by an Australian importer. These include analytical testing for cannabinoid content (THC, CBD, and a full minor cannabinoid profile), heavy metals, pesticide residues, microbial contamination, and for extracts, residual solvents. All test results must be documented in a certificate of analysis from a laboratory accredited to ISO/IEC 17025. The TGA generally expects manufacturing under GMP standards equivalent to its own PIC/S-aligned framework, meaning Thai manufacturers typically need EU-GMP or demonstrated equivalent compliance for finished products entering the Australian market.

Cold Chain and Logistics Requirements

Medical cannabis is classified as a Schedule 8 controlled substance in Australia. Shipments must comply with GDP guidelines for transport and storage throughout the supply chain. DeeMED's logistics operations for Australian-bound medical cannabis shipments use GDP-compliant temperature monitoring from origin to destination, with continuous environmental data recorded on a single-use data logger deployed inside the shipment packaging. The logger report is included in the shipment documentation package provided to the Australian importer, supporting their QP batch release process and satisfying TGA-aligned quality requirements.

Quarantine and Post-Import Verification

On arrival in Australia, shipments pass through both Australian Border Force and, for botanical materials, the Australian Department of Agriculture, Water and the Environment for biosecurity inspection. Any inconsistency between the import permit, the customs declaration, and the physical shipment documentation can result in delays or seizure. After clearing quarantine, the Australian importer conducts post-import confirmatory testing and, where applicable, formal QP batch release before the product can be distributed to dispensaries or pharmacies.

Common Failure Points

The most common reasons Thai medical cannabis shipments fail to reach Australian buyers are: documentation misalignment between the Thai ONCB export authorization and the Australian ODC import permit (product description, quantity, or supplier details do not match exactly); temperature excursions during transit without adequate monitoring records to support disposition decisions; analytical results that fall outside the Australian importer's specification on potency or contaminant limits; and failure to meet the lead times required by the importer's prescription fulfillment obligations. Every one of these failures is preventable with experienced export management and robust logistics partners who have done this route before.